Fact sheet: Janus Gbl Life Sci

Fund information
Fund name
Janus Global Life Sciences A Acc USD
Fund manager company
Janus Capital Funds
Fund type
No data available.
Fund managers
  • Andrew R Ackersince 01/05/2007
  • Ethan Lovellsince 12/01/2016
Fund objective
This Fund’s investment objective is long-term growth of capital. It pursues its objective by investing Primarily in equity securities of companies located anywhere in the world and selected for their growth potential. The Fund will invest Primarily in securities of companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. Thus, companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences. The Fund will invest at least 25% of its total assets, in the aggregate, in the following industry groups: health care; pharmaceuticals; agriculture; cosmetics/personal care; and biotechnology. The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments, subject to a limit of up to 10% of its net asset value and subject to the conditions and within the limits from time to time laid down by the Central Bank. No more than 10% of the net asset value of the Fund may be invested in securities traded on any one Developing Market and the aggregate amount of the Fund which may be invested in securities traded on the Developing Markets is 20% of the net asset value of the Fund.
Benchmark
  • MSCI World Health Care NR USD
Investment style
None
Investment method
Shares
Quick stats
1 Year return
-7.4%
1 Year rank in sector
20/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
2.44%
Fund size
£1,559m (£1,849m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
133
Top in this sector
Fund name1 Year
Variopartner SICAV MVGbMdtcF20.1%
Fidelity Gbl Health Care19.8%
BB Medtech17.4%
Charlemagne MagnaBiphrm13.2%
Pictet Health12.6%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA77.4%
    UK6.7%
    France4.5%
    Switzerland3.2%
    Israel2.3%
  • Biotechnology/Medical38.6%
    Pharmaceuticals32%
    Health Care13.1%
    Healthcare & Medical Products9.5%
    Hospital4%
  • US Equities77.4%
    UK Equities6.7%
    French Equities4.5%
    Swiss Equities3.2%
    Israeli Equities2.3%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-0.4%8.1%13%-7.4%48.3%176.7%
Sector1.8%10.4%13%-3.4%42.1%139.9%
Rank within sector27 / 3215 / 3213 / 3120 / 3110 / 249 / 24
Quartile4th2nd2nd3rd2nd2nd
Calendar performance
 YTD - 20162015201420132012
Fund-3.2%5.7%32.7%52.5%22.5%
Sector-2.8%7.2%28.1%41%16.7%
Rank within sector13 / 3121 / 2916 / 269 / 249 / 24
Quartile2nd3rd3rd2nd2nd
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
1.62
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.04
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.66
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
17.36
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
5.03
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.38
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.91
Price movement
52 week high30.1
52 week low23.14
Current bid price-
Current offer price-
Current mid price27.99
Region
1USA77.38%
2UK6.74%
3France4.46%
4Switzerland3.24%
5Israel2.34%
6Denmark2.16%
7Money Market1.6%
8Japan0.93%
9Germany0.85%
Industry sector
1Biotechnology/Medical38.6%
2Pharmaceuticals32.01%
3Health Care13.06%
4Healthcare & Medical Products9.47%
5Hospital3.97%
6Cash & Cash Equivalents1.6%
7Services0.76%
8Others0.53%
Asset type
1US Equities77.38%
2UK Equities6.74%
3French Equities4.46%
4Swiss Equities3.24%
5Israeli Equities2.34%
6Danish Equities2.16%
7Money Market1.6%
8Japanese Equities0.93%
9German Equities0.85%
Individual holdings
1AMGEN INC3.6%
2CELGENE CORP3.1%
3LILLY (ELI) & CO3.1%
4PFIZER INC2.9%
5ALLERGAN PLC2.6%
6BRISTOL MYERS SQUIBB SA2.6%
7ASTRAZENECA PLC2.5%
8AETNA INC NEW2.4%
9SANOFI2.4%
Management
Fund manager group
Janus Capital
Fund manager company
Janus Capital Funds
Fund type
No data available.
Fund objective
This Fund’s investment objective is long-term growth of capital. It pursues its objective by investing Primarily in equity securities of companies located anywhere in the world and selected for their growth potential. The Fund will invest Primarily in securities of companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. Thus, companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences. The Fund will invest at least 25% of its total assets, in the aggregate, in the following industry groups: health care; pharmaceuticals; agriculture; cosmetics/personal care; and biotechnology. The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments, subject to a limit of up to 10% of its net asset value and subject to the conditions and within the limits from time to time laid down by the Central Bank. No more than 10% of the net asset value of the Fund may be invested in securities traded on any one Developing Market and the aggregate amount of the Fund which may be invested in securities traded on the Developing Markets is 20% of the net asset value of the Fund.
Benchmark
  • MSCI World Health Care NR USD
Investment style
None
Investment method
Shares
Fund managers
NameSinceBiography
Andrew R Acker01/05/2007Andy Acker is Portfolio Manager of the Janus Global Life Sciences strategy and Portfolio Manager and Executive Vice President of Janus Global Life Sciences Fund, a position he has held since April 2007. Mr. Acker served as Co-Portfolio Manager of the Janus Aspen Global Life Sciences portfolios from October 2004. He also serves as an equity research analyst and co-team leader of the healthcare sector research team. Mr. Acker joined Janus in August 1999 as an equity research analyst, focusing on companies in the biotechnology and pharmaceutical industries. Prior to Janus, he worked as a strategy consultant for the Boston Consulting Group and as a healthcare analyst for Morgan Stanley Venture Partners.Mr. Acker received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA from the Harvard Business School, graduating with honors. Mr. Acker holds the Chartered Financial Analyst designation and has 16 years of financial industry experience.
Ethan Lovell12/01/2016Ethan Lovell is co-portfolio manager of the Janus Global Life Sciences Fund and an equity research analyst, primarily focusing on the global pharmaceutical industry. He also serves as a co-team leader of the health care sector research team. Prior to joining Janus as a research analyst in August 2007, Mr. Lovell was a director at ClearBridge Advisors covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director, then managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tools companies. He received his bachelor of arts degree from Bowdoin College with a double major in chemistry and economics and his MBA from Tulane University. Mr. Lovell has 22 years of financial industry experience.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Germany, Spain, Finland, France, United Kingdom, Hong Kong, Ireland, Italy, Luxembourg, Macau, Netherlands, Norway, Offshore, Singapore, Sweden, Taiwan - Province Of China
Janus Global Life Sciences A Acc USD
Initial charge5%
Annual charge1.5%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)2.44%
Total expense ratio (TER)2.73%
Bid price-
Offer price-
Mid price27.99
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJG04
Janus Global Life Sciences A Hedged Acc AUD
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.44%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price15.41
CurrencyAUD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJQFQ
Janus Global Life Sciences A Hedged Acc CAD
Initial charge5%
Annual charge1.5%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price-
CurrencyCAD
Price updated01/01/1900
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeKQHA
Janus Global Life Sciences A Hedged Acc CNH
Initial charge5%
Annual charge1.5%
Min single investment£15,000
Min regular saving£750
Available in ISANo
Ongoing charge (OCF)2.44%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price12.12
CurrencyCNH
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeKQHB
Janus Global Life Sciences A Hedged Acc EUR
Initial charge5%
Annual charge1.5%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)2.43%
Total expense ratio (TER)2.73%
Bid price-
Offer price-
Mid price27.9
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJI47
Janus Global Life Sciences B Acc USD
Initial charge-
Annual charge1.5%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)3.43%
Total expense ratio (TER)3.73%
Bid price-
Offer price-
Mid price23.63
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJG05
Janus Global Life Sciences E Acc USD
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.95%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price14.54
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJQ6Z
Janus Global Life Sciences E Hedged Acc EUR
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.95%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price14.21
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJQ7A
Janus Global Life Sciences I Acc EUR
Initial charge2%
Annual charge1.5%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.75%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price13.51
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeKVPP
Janus Global Life Sciences I Acc USD
Initial charge2%
Annual charge1.5%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.69%
Total expense ratio (TER)1.75%
Bid price-
Offer price-
Mid price32.28
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeZZ71
Janus Global Life Sciences I Hedged Acc EUR
Initial charge2%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.69%
Total expense ratio (TER)1.75%
Bid price-
Offer price-
Mid price26.56
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeFKM9
Janus Global Life Sciences U Acc EUR
Initial charge-
Annual charge0.8%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)0.99%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price13.69
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeKVPQ
Janus Global Life Sciences U Acc GBP
Initial charge-
Annual charge0.8%
Min single investment£2,500
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.98%
Total expense ratio (TER)1%
Bid price-
Offer price-
Mid price26.76
CurrencyGBP
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeI39J
Janus Global Life Sciences U Acc USD
Initial charge-
Annual charge0.8%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.99%
Total expense ratio (TER)0.98%
Bid price-
Offer price-
Mid price15.58
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJTSR
Janus Global Life Sciences U Hedged Acc EUR
Initial charge-
Annual charge0.8%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.98%
Total expense ratio (TER)1%
Bid price-
Offer price-
Mid price15.44
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeJTSS
Janus Global Life Sciences U Inc GBP
Initial charge-
Annual charge0.8%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)0.99%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price14.82
CurrencyGBP
Price updated22/09/2016
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeKVPS
Janus Global Life Sciences U Inc USD
Initial charge-
Annual charge0.8%
Min single investment£2,500
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)1%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price11.98
CurrencyUSD
Price updated22/09/2016
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeKVPR
Janus Global Life Sciences V Acc USD
Initial charge5%
Annual charge1.5%
Min single investment£250,000
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)2.43%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.85
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeMTTF
Janus Global Life Sciences V Hedged Acc EUR
Initial charge5%
Annual charge1.5%
Min single investment£250,000
Min regular saving£100
Available in ISANo
Ongoing charge (OCF)2.43%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.73
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeMTTG
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.